Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.
about
Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Plasma YKL-40 as a biomarker f ...... se 3 randomized AVAglio trial.
@en
Plasma YKL-40 as a biomarker f ...... se 3 randomized AVAglio trial.
@nl
type
label
Plasma YKL-40 as a biomarker f ...... se 3 randomized AVAglio trial.
@en
Plasma YKL-40 as a biomarker f ...... se 3 randomized AVAglio trial.
@nl
prefLabel
Plasma YKL-40 as a biomarker f ...... se 3 randomized AVAglio trial.
@en
Plasma YKL-40 as a biomarker f ...... se 3 randomized AVAglio trial.
@nl
P2093
P2860
P356
P1433
P1476
Plasma YKL-40 as a biomarker f ...... se 3 randomized AVAglio trial.
@en
P2093
Julia S Johansen
Mogens K Boisen
Nicola Consalvo
P2860
P304
P356
10.18632/ONCOTARGET.22886
P407
P577
2017-12-04T00:00:00Z